Clinical Trial Update: A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating Axatilimab for chronic graft-versus-host disease in participants who have received at least two prior systemic therapies;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Axatilimab (axatilimab)

Snippet

Sponsor: Incyte Corporation | Conditions: Chronic Graft-versus-host-disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING